Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding 'Business stability and Sustainability Report '.
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Akums Drugs and Pharmaceuticals has submitted the notice for its 21st Annual General Meeting scheduled for Friday, 18th July 2025 at 11:00 am via Video Conference, along with its first Integrated Annual Report for FY 2024-25, which includes the Business Responsibility and Sustainability Report (BRSR). The company, listed on NSE and BSE since August 6, 2024, reported FY25 revenue of ₹4,118.20 Crores, Adjusted EBITDA of ₹512.73 Crores, and Profit After Tax of ₹343.80 Crores. Key highlights include a landmark EUR 200 Million CDMO contract for the European market, R&D investment of ₹130 Crores yielding 31 DCGI and 117 FSSAI approvals, and a net cash position of ₹566 Crores. The company operates 14 manufacturing facilities, serves 1,600+ clients across 70+ countries, and employs 17,500+ people.
This is primarily a routine regulatory filing for AGM convening and annual report submission, so no immediate stock price impact is expected. However, the report's strong FY25 financials, the major European CDMO contract, and the BRSR disclosures provide positive fundamental context for shareholders ahead of the AGM.